EGF and neoplasm: RNAseq-based transcriptomic profiling of cells at each stage of tumor cell growth under 1μM lapatinib, followed by gene set enrichment analysis of corresponding signatures, revealed that the resistance and relapse phases display a signature consistent with the activation of neuregulin (NRG1) and EGF signaling (Fig 1D and 1E).